HORIZON MICROTECHNOLOGIES COMBINES MICRO-AM WITH ADVANCED COATINGS FOR FUNCTIONALISED 3D MICROFLUIDIC DEVICES

Why It Matters

Merging 3D printing with functional coatings dramatically reduces microfluidic fabrication complexity, cutting time‑to‑market and enabling fully integrated, patient‑facing devices.

Key Takeaways

• Monolithic 3D microfluidics printed, no bonding required.
• Post‑print coatings enable wetting control and embedded electrodes.
• Biocompatible polymers provide safe patient‑contact devices.
• Integrated optics allow direct imaging without extra windows.
• Accelerates development from CAD to functional hardware.

Pulse Analysis

Microfluidic platforms have long been hampered by multi‑step lithography, bonding, and metallisation processes that inflate cost and prolong development. Horizon’s micro‑AM approach sidesteps these bottlenecks by fabricating the entire fluidic architecture—including channels, reservoirs, and microneedle arrays—in a single polymer print. This monolithic construction not only removes the risk of inter‑layer leaks but also simplifies the supply chain, allowing engineers to move from computer‑aided design to a physical prototype in hours rather than weeks.

The real differentiator lies in Horizon’s post‑build coating toolbox. By tailoring surface energy, the coatings ensure reliable priming and eliminate trapped bubbles, which are common failure points in lab‑on‑a‑chip diagnostics. Conductive additives create embedded micro‑electrodes and conductive pathways, supporting electrokinetic flow control, electrophoretic separation, and on‑chip electrochemical sensing. Simultaneously, optically clear regions are preserved for fluorescence readout or particle tracking, eliminating the need for separate windows or lenses. The combination of fluidic, electrical, and optical functionality in one printed part unlocks new design freedoms for point‑of‑care testing and minimally invasive sampling.

From a business perspective, this integrated workflow shortens the product development timeline and reduces capital expenditure on clean‑room equipment. Companies can iterate designs rapidly, validate performance in‑house, and scale production without re‑tooling. The biocompatibility of the base polymers expands the addressable market to include patient‑facing devices such as microneedle‑based drug delivery and continuous monitoring patches. As regulatory pathways for additive‑manufactured medical devices mature, Horizon’s solution positions it as a strategic partner for firms seeking to accelerate time‑to‑market while maintaining high reliability and functional integration.